In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|2|627-635

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.2, 2015-02, pp. : 627-635

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 1036-1047

John Wiley & Sons Inc

Access to resources Recommend Favorite

90 Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness

By Xing Minzhi   Kokabi Nima   Camacho Juan C   Kooby David A   El-Rayes Bassel F   Kim Hyun S  

Journal of Comparative Effectiveness Research, Vol. 2, Iss. 4, 2013-07 ,pp. : 435-444

Future Medicine

Access to resources Recommend Favorite

Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization

By  

Oncology, Vol. 87, Iss. 6, 2014-09 ,pp. : 330-341

Karger

Access to resources Recommend Favorite

Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90

By  

Oncology, Vol. 84, Iss. 5, 2013-04 ,pp. : 311-318

Karger

Access to resources Recommend Favorite

Yttrium-90 Radioembolization for Hepatocellular Carcinoma: What We Know and What We Need to Know

By  

Oncology, Vol. 84, Iss. 1, 2013-02 ,pp. : 34-39

Karger

Access to resources Recommend Favorite